Dentons US Hired New Healthcare Practice Partner
The firm added a specialist in FDA regulatory and corporate matters to advise pharmaceutical and medical device clients.
Updated on Oct. 13, 2026 in Healthcare
Dentons US announced on Monday the addition of Schevon Salmon as a partner within its healthcare practice. Salmon joins the firm from K&L Gates to focus on regulatory and transactional work for life sciences companies.
Why it matters
The appointment strengthens the firm's capacity to navigate complex FDA regulations and corporate deal-making for clients in the pharmaceutical, biotechnology, and medical device sectors. These sectors currently face shifting compliance requirements that demand specialized legal counsel.
The firm expanded its healthcare team with one new partner hire. The total size of the practice and the firm's specific hiring budget remain undisclosed.
The players
Schevon Salmon
An attorney specializing in FDA regulatory matters and corporate transactions for life sciences entities.
Dentons US
A major global law firm providing legal services to corporate clients across various regulated industries.
K&L Gates
A large, international law firm where Salmon previously practiced.
The details
Salmon will work with pharmaceutical, biotechnology, and medical device companies on corporate transactions and federal regulatory matters. This move reflects a focus on integrating legal oversight with the technical product-approval hurdles inherent in the life sciences industry. The firm manages these client needs by balancing high-stakes compliance with corporate strategy during mergers or product development cycles.
Timeline
October 12, 2026: Dentons US announced the hiring of Salmon.
Market Landscape
This appointment follows a broader industry trend where law firms scale their specialized practices to meet the complex requirements of the FDA regulatory framework. Firms are increasingly prioritizing partners who can bridge the gap between corporate deal-making and compliance oversight.
Operators in the pharmaceutical and medical device sectors should ensure their current legal counsel has the specific expertise to handle evolving FDA requirements alongside corporate transactions. Businesses seeking to scale or sell should evaluate whether their advisory teams provide sufficient regulatory depth to avoid deal-breaking compliance delays.
The takeaway
Specialized regulatory oversight is a core component of maintaining operational continuity during corporate transitions in the life sciences sector. Review your firm's current outside counsel to confirm their team includes specific, documented expertise in recent FDA policy shifts.
Further reading
For more on industry shifts, visit the Healthcare section.
Source note: This article includes information reported by Bloomberglaw.
